Affimed Therapeutics AG
Affimed Therapeutics AG: Affimed raises EUR 15.5 million in a Series D financing round
Affimed Therapeutics AG / Key word(s): Capital Increase Affimed raises EUR 15.5 million in a Series D financing round Heidelberg, Germany; October 8, 2012: Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful closing of a Series D financing round of EUR 15.5 million. The proceeds from this transaction will be used to fund the clinical development of Affimed’s therapeutic pipeline that consists of two TandAb products, AFM11 and AFM13. AFM13, a CD30/CD16A TandAb is currently being evaluated in a phase I clinical trial for the treatment of Hodgkin’s Lymphoma. The results of the trial are expected by December 2012. AFM11 a CD19/CD3 TandAb is in the late stage preclinical development and it is expected to enter phase I clinical studies in 2013. Both candidates have unique properties as shown in preclinical studies. TandAbs are innovative bispecific tetravalent antibodies that are based on the company’s proprietary technology. This versatile technology produces biotherapeutic leads that are being developed for the treatment of oncological and anti-inflammatory diseases. In oncology indications TandAbs bind target molecules on the surface of tumor cells and immune cells (T cells or NK cells), triggering the activation of the immune system and leading to tumor cell destruction. The Series D financing round is lead by existing investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed. Dr. Adi Hoess, CEO of Affimed, commented: ‘AFM11 and AFM13 represent real opportunities to generate highly potent medicines for patients with severe malignancies and furthermore could create substantial value for investors. The closing of our Series D financing will allow us to further advance our programs and to generate important clinical data’. For further information please contact:
About Affimed Therapeutics AG: About TandAbs(R): Affimed has developed different kinds of TandAbs(R) for specific indications. While RECRUIT-TandAbs(R) are applied to oncology, BiBLOCK- and PROLONG-TandAbs(R) are developed for the treatment of autoimmune and inflammatory diseases.
End of Corporate News 08.10.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
187894 08.10.2012 |